ecrin-mdr-crcClinical2014Colorectal CancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2630892Japan11ECRIN MDRActive, not recruitingfalsePhase II study to examine efficacy prediction of Regorafenib with FDG-PET/CT in patients with treatment-refractory metastatic colorectal cancerInterventions: Regorafenib:160 mg orally, once daily for 3 weeks and one week rest in each cycle. Primary outcome(s): Response rate in change of SUVmax in primary target lesion (the highest value in SUVmax at baseline) at 4 weeks after treatment by Regorafenib. Study Design: Single arm Non-randomized2014-11-152630892JPRN-UMIN000015563